Research Papers:
Clinicopathological signature of p21-activated kinase 1 in prostate cancer and its regulation of proliferation and autophagy via the mTOR signaling pathway
Metrics: PDF 2083 views | HTML 4895 views | ?
Abstract
Zhanyu Wang1, Guojin Jia1, Yan Li1, Jikai Liu1, Jinfang Luo2, Jihong Zhang3, Guoxiong Xu3,*, Gang Chen1,*
1Department of Urology, Jinshan Hospital, Fudan University, Shanghai 201508, People’s Republic of China
2Department of Pathology, Jinshan Hospital, Fudan University, Shanghai 201508, People’s Republic of China
3Center Laboratory, Jinshan Hospital, Fudan University, Shanghai 201508, People’s Republic of China
*These authors contributed equally to this work
Correspondence to:
Gang Chen, email: [email protected]
Guoxiong Xu, email: [email protected]
Keywords: PAK1, prostate cancer, mTOR signaling, rapamycin, MYH1485
Received: August 02, 2016 Accepted: January 23, 2017 Published: February 06, 2017
ABSTRACT
Prostate cancer (PCa) is one of the most common malignant tumors in men. The etiology and pathogenesis of PCa remain unclear. P21-activated kinase 1 (PAK1) is a member of a family of serine/threonine kinases and regulates cell growth and contributes to tumor invasion and metastasis. However, the association of PAK1 with PCa tumorigenesis and in particular with cell autophagy remains unknown. We found that the positive expression of PAK1 was significantly increased in PCa patients compared with BPH patients (P < 0.05). The expression of PAK1, p-PAK1 and LC3B1 in DU145 was increased by the activator of mTOR MYH1485. The expression of PAK1, p-PAK1, mTOR and Beclin1 decreased in PAK1-shRNA expressing DU145 cell. Knocking down of PAK1 inhibited DU145 cell growth, invasion and migration in vitro, and inhibited tumor growth in vivo. Our study demonstrated that PAK1 is upregulated in PCa and regulated by the mTOR signaling pathway and contributes to tumor autophagy. Thus, PAK1 may be a potential tumor marker and therapeutic target of PCa.
![Creative Commons License](/images/80x15.png)
PII: 15124